Clinical Trial Update: Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares the combination of trastuzumab and regorafenib versus regorafenib alone for advanced hepatocellular carcinoma after first-line…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Stivarga (regorafenib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING